| Objective:Using85%hepatectomy model to investigate the role and impact ofsomatostatin for postoperative survival and liver regeneration.Methods:Experimental Animals: SD (Sprague-Dawley) rats, either male or female; bodyweight:210to290g; experimental groups: animals were randomly divided into fivegroups: A, B, C groups were of10rats in each. D, E groups were of18rats in each.Group A:85%hepatectomy; Group B:85%hepatectomy and using somatostatin;Group C: sham operation group, only turned the lobe of the liver, not liver resection.Postoperative survival rate and serum ALT and AST’s levels were detected in eachgroup. Group D: treated as group A,6rats were sacrificed at24h,48h and72hpostoperative respectively; Group E: treated as group B,6rats were sacrificed at24h,48h and72h postoperative respectively, by the above two groups of rats to detect therelative liver weight [remnant liver weight (g)/body weight (kg)] and portal veinpressure, by immunohistochemistry to detect the expression of PCNA [proliferatingcell nuclear antigen].Results:①Survival rate: In Group A, two rats died in24h, three rats died in48h, two ratssurvival beyond72h. In Group B, no rats died in24h,2rats died in48h,6ratssurvival more than72h. The survival rate of Group B was significantly higher thangroup A (P <0.05). In group C, no rats died at each time point, significantly higherthan A, B groups (P <0.05).②Serum ALT and AST levels: In group A, ALT and AST levels increasedsignificantly in30minutes after85%hepatectomy, were304.8±40.8U/ml and370.6±54.5U/ml,48h reached the maximum value, were655.3±67.9U/ml and1305.8±115.5U/ml, and then began to decline. In group B, after30minutes, ALT and ASTwere242.5±27.1U/ml and354.6±52.6U/ml, reached the maximum value at48h,were655.3±67.9U/ml and1305.8±115.5U/ml, and then began to decline. In each time period, A, B groups were significant difference (P <0.01). In group C,each timepoint ALT and AST’s levels was significantly lower than A, B groups, there was asignificant difference (P <0.01), compared with A, B groups.③Portal pressure: In the surgery, portal vein pressure of group D and group Ewere11.2±0.12mmHg and10.9±0.24mmHg, the two groups weresignificantly different (P <0.05).10min after surgery, portal vein pressure of group Dand group E began to rise sharply, had reached19.1±0.21mmHg and15.3±0.22mmHg, group D was significantly higher than group E (P <0.01). And after,portal vein pressure of the two groups decreased. In each time point, group E’s portalpressure was significantly lower than it in the group D (P <0.01).④PCNA index: PCNA index in group D and group E were21.15±1.32and22.31±1.45respectively at24h after85%hepatectomy, the two groups showed nosignificant difference (P>0.05), at48h, the group of D and E’s PCNA index reachedthe highest value, were47.62±2.75and30.64±2.48, group D was significantlyhigher than the group E (P <0.01), at72h, the group of D and E’s PCNA indexdeclined, were33.53±1.35and25.45±1.68, group D was significantly higherthan the group E (P <0.01).⑤The relative liver weight: Relative liver weight of group D and group E were6.14±0.56and6.58±0.78respectively at24h after85%hepatectomy; the twogroups had no significantly different (P>0.05), at48h, the groups D and E’s relativeliver weight were11.25±1.54and12.64±1.29, the two groups showed nosignificant difference (P>0.05), at72h, the groups D and E’s relative liver weightwere25.78±1.76,20and14±1.42, group D was significantly higher thanGroup E, there was a significant difference (P <0.05).Conclusion:1. Somatostatin could reduce significantly the portal vein pressure, reduce bloodALT, AST levels, and improve the survival rate after the85%hepatectomy.2. The use of somatostatin could not improve the liver regeneration after85%hepatectomy; long-term use might even inhibit the process of liver regeneration. |
PDF Full Text Request